Skip to content

ENGN

enGene Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · CA

$1.91
+0.00%
Ask drillr

Income statement

MetricTTM2025202420232022
Revenue
Total Revenue
Cost of Revenue547.0K
Gross Profit(547.0K)
Operating Expenses
R&D Expense96.3M94.5M38.3M16.5M15.5M
SG&A Expense42.7M28.7M24.0M8.5M3.3M
General & Admin Expense42.7M28.7M24.0M8.5M3.3M
Selling & Marketing Expense
Other Expenses(2.5M)1.1M700.0K
Total Operating Expenses136.5M123.2M62.3M26.1M19.4M
Cost and Expenses136.6M123.2M62.3M26.1M19.4M
Operating Income (EBIT)(4.7M)(123.2M)(62.3M)(26.1M)(19.4M)
Non-Operating
Interest Income4.5M9.4M10.4M1.1M129.0K
Interest Expense3.1M3.0M2.8M5.0M1.4M
Net Interest Income6.7M6.4M7.6M(3.8M)(1.3M)
Other Non-Op Income/Expense(717.0K)5.9M7.1M(73.8M)(5.0M)
Non-Operating Income (excl Interest)127.9M(8.9M)(9.9M)68.9M3.6M
EBT (Pre-Tax Income)(5.4M)(117.3M)(55.2M)(99.9M)(24.4M)
Income Tax Expense(497.0K)(19.0K)17.0K22.0K
Bottom Line
Net Income(4.9M)(117.3M)(55.1M)(99.9M)(24.5M)
Earnings from Cont. Ops(4.9M)(117.3M)(55.1M)(99.9M)(24.5M)
Earnings from Discont. Ops
Bottom Line Net Income(4.9M)(117.3M)(55.1M)(104.7M)(29.0M)
Per Share
Basic EPS($0.28)($2.29)($1.46)($4.24)($1.84)
Diluted EPS($0.28)($2.29)($1.46)($4.24)($1.84)
Revenue Per Share$0.00$0.00$0.00$0.00$0.00
Shares
Basic Shares Outstanding69.7M51.1M44.6M23.6M15.8M
Diluted Shares Outstanding69.7M51.1M44.6M23.6M15.8M
Profitability Metrics
EBITDA(131.9M)(113.8M)(52.0M)(94.8M)(22.8M)
D&A718.0K509.0K323.0K175.0K238.0K
EBIT(132.6M)(114.3M)(52.4M)(94.9M)(23.0M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jul 1, 2026